Upadacitinib approved in EU for use in psoriatic arthritis and active ankylosing spondylitis

Approval was based on three clinical trials; SELECT-PsA 1, SELECT-PsA 2, which found superiority to placebo, and non-inferioirty to adalimumab for psoriatic arthritis, and SELECT-AXIS 1 which found superiority to placebo for ankylosing spondylitis.

Source:

PharmaTimes